{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T03:46:58Z","timestamp":1777348018460,"version":"3.51.4"},"reference-count":14,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objectives.<\/jats:bold>\n                    Immune reconstitution therapies (IRT), which include antibody-based cell-depleting therapies targeting CD52+ (alemtuzumab) or CD20+ (rituximab, ocrelizumab) leukocytes, are approved for the treatment of multiple sclerosis. Thyroid autoimmunity is a common adverse effect of alemtuzumab treatment, Graves\u2019 disease (GD) being the most prevalent manifestation. To date, thyroid autoimmunity events have not been reported with CD20-targeting monoclonal antibodies.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Case Report.<\/jats:bold>\n                    A 59-year-old woman with primary progressive multiple sclerosis with no prior personal history of thyroid disease or autoimmunity, was diagnosed with GD 6 months following the first ocrelizumab infusion. She was asymptomatic and had no signs of ophthalmopathy. Due to the temporal association of GD diagnosis with ocrelizumab infusion, absence of symptoms and our experience with alemtuzumab-induced GD, we decided for an active surveillance strategy and antithyroid drugs were not started. She underwent spontaneous resolution of hyperthyroidism with thyroid-stimulating hormone (TSH) receptor antibodies (TRAb) negativity and a mild and transitory period of subclinical hypothyroidism, while she continued the biannually ocrelizumab administration schedule. To present date, she has maintained close clinical and biochemical surveillance with normal TSH, free thyroxine (fT4) and free triiodothyronine (fT3) levels and undetectable TRAb.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions.<\/jats:bold>\n                    This is the first case of GD reported after ocrelizumab administration. The timing, onset and course of this case is similar to alemtuzumab-induced GD, usually interpreted as an \u201cimmune reconstitution syndrome\u201d; however, ocrelizumab cell count depletion is inferior in severity, cell population affected and duration of depletion. This case highlights the importance of pre-screening and follow-up with thyroid function tests in patients treated with ocrelizumab. As a novel therapeutic antibody, further investigation is required to unravel the causes of thyroid autoimmunity.\n                  <\/jats:p>","DOI":"10.2478\/enr-2021-0018","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T03:29:04Z","timestamp":1631676544000},"page":"169-173","source":"Crossref","is-referenced-by-count":5,"title":["Graves\u2019 disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis"],"prefix":"10.2478","volume":"55","author":[{"given":"Diana Borges","family":"Duarte","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism , Centro Hospitalar e Universitario do Porto , Oporto , Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Martins da","family":"Silva","sequence":"additional","affiliation":[{"name":"Department of Neurology , Centro Hospitalar e Universitario do Porto , Oporto , Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Freitas","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism , Centro Hospitalar e Universitario do Porto , Oporto , Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism , Centro Hospitalar e Universitario do Porto , Oporto , Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"key":"2026042722155278398_j_enr-2021-0018_ref_001","doi-asserted-by":"crossref","unstructured":"Antonelli A, Fallahi P, Elia G, Ragusa F, Paparo SR, Ruffilli I, Patrizio A, Gonnella D, Giusti C, Virili C, Centanni M, Shoenfeld Y, Ferrari SM. Graves\u2019 disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Pract Res Clin Endocrinol Metab 34, 101388, 2020.10.1016\/j.beem.2020.10138832059832","DOI":"10.1016\/j.beem.2020.101388"},{"key":"2026042722155278398_j_enr-2021-0018_ref_002","doi-asserted-by":"crossref","unstructured":"el Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedus L. B lymphocyte depletion with the monoclonal antibody rituximab in Graves\u2019 disease: a controlled pilot study. J Clin Endocrinol Metab 92, 1769\u20131772, 2007.10.1210\/jc.2006-238817284622","DOI":"10.1210\/jc.2006-2388"},{"key":"2026042722155278398_j_enr-2021-0018_ref_003","doi-asserted-by":"crossref","unstructured":"el Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedus L, Nielsen CH. Treatment of Graves\u2019 disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 130, 252\u2013258, 2009.10.1016\/j.clim.2008.09.00718964302","DOI":"10.1016\/j.clim.2008.09.007"},{"key":"2026042722155278398_j_enr-2021-0018_ref_004","doi-asserted-by":"crossref","unstructured":"Hausler D, Hausser-Kinzel S, Feldmann L, Torke S, Lepennetier G, Bernard CCA, Zamvil SS, Bruck W, Lehmann-Horn K, Weber MS. Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease. Proc Natl Acad Sci U S A 115, 9773\u20139778, 2018.10.1073\/pnas.1810470115616680530194232","DOI":"10.1073\/pnas.1810470115"},{"key":"2026042722155278398_j_enr-2021-0018_ref_005","doi-asserted-by":"crossref","unstructured":"Heemstra KA, Toes RE, Sepers J, Pereira AM, Corssmit EP, Huizinga TWJ, Romijn JA, Smit JW. Rituximab in relapsing Graves\u2019 disease, a phase II study. Eur J Endocrinol 159, 609\u2013615, 2008.10.1530\/EJE-08-008418628345","DOI":"10.1530\/EJE-08-0084"},{"key":"2026042722155278398_j_enr-2021-0018_ref_006","doi-asserted-by":"crossref","unstructured":"Kurozumi A, Okada Y, Arao T, Narisawa M, Torimoto K, Yamamoto S, Tanaka Y. Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves\u2019 disease and type 1 diabetes mellitus: a case report. Endocr J 62, 69\u201375, 2015.10.1507\/endocrj.EJ14-015225273396","DOI":"10.1507\/endocrj.EJ14-0152"},{"key":"2026042722155278398_j_enr-2021-0018_ref_007","doi-asserted-by":"crossref","unstructured":"Lunemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H. Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nat Rev Neurol 16, 56\u201362, 2020.10.1038\/s41582-019-0268-z31649335","DOI":"10.1038\/s41582-019-0268-z"},{"key":"2026042722155278398_j_enr-2021-0018_ref_008","doi-asserted-by":"crossref","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376, 209\u2013220, 2017.10.1056\/NEJMoa160646828002688","DOI":"10.1056\/NEJMoa1606468"},{"key":"2026042722155278398_j_enr-2021-0018_ref_009","doi-asserted-by":"crossref","unstructured":"Muller I, Willis M, Healy S, Nasser T, Loveless S, Butterworth S, Zhang L, Draman MS, Taylor PN, Robertson N, Dayan CM, Ludgate ME. Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy: Evidence that TRAb may precede thyroid dysfunction by many years. Thyroid 28, 1682\u20131693, 2018.10.1089\/thy.2018.023230351224","DOI":"10.1089\/thy.2018.0232"},{"key":"2026042722155278398_j_enr-2021-0018_ref_010","doi-asserted-by":"crossref","unstructured":"Muller I, Moran C, Lecumberri B, Decallonne B, Robertson N, Jones J, Dayan CM. 2019 European Thyroid Association Guidelines on the management of thyroid dysfunction following immune reconstitution therapy. Eur Thyroid J 8, 173\u2013185, 2019.","DOI":"10.1159\/000500881"},{"key":"2026042722155278398_j_enr-2021-0018_ref_011","doi-asserted-by":"crossref","unstructured":"Salvi M, Vannucchi G, Campi I, Curro N, Dazzi D, Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck-Peccoz P. Treatment of Graves\u2019 disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156, 33\u201340, 2007.10.1530\/eje.1.0232517218723","DOI":"10.1530\/eje.1.02325"},{"key":"2026042722155278398_j_enr-2021-0018_ref_012","doi-asserted-by":"crossref","unstructured":"Salvi M, Vannucchi G, Curro N, Campi I, Covelli D, Dazzi D, Simonetta S, Guastella C, Pignataro L, Avignone S, Beck-Peccoz P. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 100, 422\u2013431, 2015.10.1210\/jc.2014-3014431889925494967","DOI":"10.1210\/jc.2014-3014"},{"key":"2026042722155278398_j_enr-2021-0018_ref_013","doi-asserted-by":"crossref","unstructured":"Sellner J, Rommer PS. Immunological consequences of \u201cimmune reconstitution therapy\u201d in multiple sclerosis: A systematic review. Autoimmun Rev 19, 102492, 2020.10.1016\/j.autrev.2020.10249232062028","DOI":"10.1016\/j.autrev.2020.102492"},{"key":"2026042722155278398_j_enr-2021-0018_ref_014","doi-asserted-by":"crossref","unstructured":"Weetman A. Immune reconstitution syndrome and the thyroid. Best Pract Res Clin Endocrinol Metab 23, 693\u2013702, 2009.10.1016\/j.beem.2009.07.00319942146","DOI":"10.1016\/j.beem.2009.07.003"}],"container-title":["Endocrine Regulations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/enr-2021-0018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T03:19:06Z","timestamp":1777346346000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/enr-2021-0018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,9,13]]},"published-print":{"date-parts":[[2021,7,1]]}},"alternative-id":["10.2478\/enr-2021-0018"],"URL":"https:\/\/doi.org\/10.2478\/enr-2021-0018","relation":{},"ISSN":["1336-0329"],"issn-type":[{"value":"1336-0329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]}}}